JSPRW
Jasper Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.01
−38.04%Aug 14, 2026, 00:00 UTC
Jasper Therapeutics reported a net loss of $2.76 million for Q2 2026, with diluted loss per share of $0.10, and cash and cash equivalents of $7.3 million as of June 30, 2026.
Jul 17, 2026, 00:00 UTC
Jasper Therapeutics raised $132 million in a private stock offering.
Source:Jul 17, 2026, 00:00 UTC
Jasper Therapeutics acquired Kira Pharmaceuticals via a reverse triangular merger, with consideration of Jasper common and convertible preferred stock.